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any significant drug interactions.2,7 Current
preparations contain lower doses of estro-
gen; a drug interaction causing decreased
efficacy of OCs may be more likely.1,2,4,5 
More than 200 occurrences have been
reported anecdotally, in adverse-event
■ Evidence summary
Oral contraceptives (OC) are taken by
approximately 70 million women world-
wide.2 Studies suggest there is extreme vari-
ation in plasma concentrations of active
hormone between individuals, even without
Do antibiotics interfere with the efficacy
of oral contraceptives? 
Among antibiotics, only rifampin has been demon-
strated to interfere with the effectiveness of oral
contraceptives (OCs) (strength of recommendation
[SOR]: C, limited case series).1–4 There is little con-
vincing evidence to show a systematic interaction
between other antibiotics and oral contraceptive
steroids (SOR: B, based on systematic reviews,
case reports, and pharmacologic studies).
However, current studies may not have separately
evaluated the minority of women whose 
metabolism of contraceptive steroids makes them
more vulnerable to OC failure.1–3,5,6 Given the 
significant consequences of unintended pregnancy,
some experts recommend a conservative approach,
including patient education and backup forms of
birth control1,7 (SOR: C, expert opinion).
E V I D E N C E - B A S E D A N S W E R
Discussing drug interactions improves patient
awareness and may prevent unplanned pregnancies
Identifying the patient at risk of OC failure is difficult.
Add to that the unknown impact of antibiotics, and
risk assessment becomes virtually impossible.
Although rifampin is the only antibiotic shown at
this time to interfere with the effectiveness of OCs,
others may have the same effect. Thus, in my
judgment, a conservative approach is best. Before
prescribing oral contraception and antibiotics, 
I advise my patients that there may be a risk of
contraceptive failure. As a result, many choose 
to use an additional nonhormonal method while 
taking antibiotics. 
Minal Patel, MD
Baylor College of Medicine, Houston, Tex
C L I N I C A L C O M M E N T A R I E S
Karen L. Bauer, MD, Diane Wolf, MSLS
Christiana Care Health System, Wilmington, Delaware
Discussing the risk may not be 
the most beneficial use of your time
If antibiotics interact with OCs in a clinically 
significant way, the effect is uncommon and 
unpredictable. Discussing this with the patient may
lead to undue anxiety, avoidance of needed anti-
biotics, nonadherence with the antibiotic or OCs
or both, and, because of the time this discussion
might take, neglect of other beneficial discussions
(eg, smoking cessation). On both sides, risks and
benefits are small. I don’t bring it up if I’m 
prescribing a short course of an antibiotic. I might 
if I’m starting a long-term antibiotic (eg, for acne),
knowing the patient will read the patient informa-
tion from the pharmacy, which raises the concern. 
Daniel C. Vinson, MD, MSPH
Department of Family and Community Medicine, 
University of Missouri-Columbia 
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It is possible that
a true interaction
between OCs and
antibiotics may
occur in a small
subset of women
with low steroid
hormone levels
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monitoring systems, and in retrospective
surveys of OC failure for women treated
with various antibiotics. But no prospective
RCTs have been done, and most of the ret-
rospective case series have not used control
groups.1 All the pharmacokinetic and retro-
spective studies have a small sample size,
which may conceal an interaction within
the normal OC failure rate.1,2 Given this, 4
retrospective surveys on women taking
OCs who were treated with antibiotics
(erythromycin, tetracycline, minocycline,
penicillin, ampicillin, sulfa, cephalosporins)
found OC failure rates of 1.2% to 1.6%,
within the range for typical populations.1
These data are subject to recall bias and
underreporting of poor compliance. 
Multiple studies have looked at OC
serum levels with and without antibiotic
treatment.1 These studies show that the
coadministration of antibiotics (ampicillin,
tetracycline, doxycycline, metronidazole,
erythromycin, clarithromycin, temafloxacin,
fluconazole, ciprofloxacin, or ofloxacin) did
not reduce serum levels of either the estro-
gen or progestin components of the oral
contraceptives.1,2 Rifampin is a potent
inducer of the cytochrome P450 system,
capable of reducing serum estrogen and
progestin levels, and a small-scale study has
suggested breakthrough ovulation among 
2 of 9 women taking oral contraceptives
and rifampin.2,8
It is possible, however, that a true inter-
action between antibiotics and OCs may
only manifest itself in the very small subset
of women who have unusually low steroid
hormone levels.1–3 The women most likely
to have pill failure are those with low rates
of ethinyl estradiol hydroxylation, high
rates of hepatic conjugation, low plasma
concentrations of ethinyl estradiol, exten-
sive intestinal hydrolysis of estrogen conju-
gates, or gut flora particularly susceptible
to the antibiotic.1,3 These women may be
identified by symptoms of breakthrough
bleeding, cramping, nausea, vomiting or
diarrhea, or by unwanted pregnancy.2,3
Unfortunately, they cannot be identified by
any routine diagnostic tests. The most 
conservative approach emphasizes patient
education and additional forms of non-
hormonal contraception for any woman 
on OCs during any antibiotic therapy and
for at least 1 week after treatment.1,3
Recommendations from others
Williams Obstetrics (2001) states that some
antibiotics still have in their labeling that
they may reduce the effectiveness of OCs,
but that this is likely not true.9 They do not
have a recommendation on how to handle
this. The MMWR Recommendations and
Reports (2003) recommend that women of
reproductive potential on OCs who are also
taking rifampin should add a barrier
method of contraception.10 The World
Health Organization (WHO) states that
there have been suspicions that broad-spec-
trum antibiotics may lower OC effectiveness
based on case reports, but that pregnancy
rates are similar among women on OCs and
women on both OCs and antibiotics.11
According to the WHO 2003 Expert
Working Group, broad-spectrum antibiotics
are in Medical Eligibility Criteria category 1,
which allows use in any circumstances.11
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